Fundraising Fox

Prexton Therapeutics

acquired by Lundbeck

Copenhagen, DK · Founded 1915 · 6,027 employees on LinkedIn · 5 known investors

Prexton Therapeutics was a biopharmaceutical company developing novel therapies for Parkinson's disease, including its lead mGluR4 modulator candidate foliglurax. Acquired by Lundbeck in 2018.

Investors · 5

Competitors · 1

by search overlap

Companies competing with Prexton Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Frequently asked questions

What does Prexton Therapeutics do?
Prexton Therapeutics was a biopharmaceutical company developing novel therapies for Parkinson's disease, including its lead mGluR4 modulator candidate foliglurax. Acquired by Lundbeck in 2018.
Who are Prexton Therapeutics's investors?
Prexton Therapeutics's investors include Cardinal Partners, M Ventures, Seroba Life Sciences, Sunstone Capital, Ysios Capital.
Who acquired Prexton Therapeutics?
Prexton Therapeutics was acquired by Lundbeck.
Where is Prexton Therapeutics headquartered?
Prexton Therapeutics is headquartered in Copenhagen, DK.